Advanced search×

Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.

N C NC Tebbutt, F F Murphy, D D Zannino, K K Wilson, M M MM Cummins, E E Abdi, A H AH Strickland, R M RM Lowenthal, G G Marx, C C Karapetis, J J Shannon, D D Goldstein, S S SS Nayagam, R R Blum, L L Chantrill, R J RJ Simes, T J TJ Price, and

Ann Oncol 22(8):1834-8 (2011) PMID 21273347

Bevacizumab is an antiangiogenic mAb with efficacy against several cancers, but it is associated with risk of arterial thromboembolism (ATE). Further data are needed to determine the safety of bevacizumab.

DOI: 10.1093/annonc/mdq702
Version: za2963e q8za6 q8zbc q8zcb q8zd9 q8zeb q8zf8 q8zgb

Similar articles you may find interesting…

  1. Pathological healing response of explanted MitraClip devices.
    Elena Ladich, Mary Beth Michaels, ... Renu Virmani

    Circulation 123(13):1418-27 (2011) PMID 21422390

    I collagen), incorporating the device components with complete encapsulation by organized, fibrous growth. In long-term devices with minimal surgical disruption, a fibrous tissue bridge (mean area, 7.39±4.3 mm(2)) was observed over and between the device arms, resulting in atrial tissue continuity...
  2. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestin...
    Niall C NC Tebbutt, Kate K Wilson, ... Timothy J TJ Price

    J Clin Oncol 28(19):3191-8 (2010) PMID 20516443

    We compared CB with capecitabine and CBM with capecitabine for progression-free survival (PFS). Secondary end points included overall survival (OS), toxicity, response rate (RR), and quality of life (QOL). Results Median PFS was 5.7 months for capecitabine, 8.5 months for CB, and 8.4 months for CBM...
  3. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort...
    Barbara Bartmeyer, Claudia Kuecherer, ... German HIV-1 Seroconverter Study Group

    PLoS One 5(10):e12718 (2010) PMID 20949104

    View PDF